Core Viewpoint - The company, Fuhong Hanlin (02696), has entered into a collaboration agreement with Aohong Pharmaceutical for exclusive commercialization rights of a product in a specific region and field, enhancing its portfolio in the breast cancer treatment market [1] Group 1: Collaboration Agreement - The collaboration agreement was signed on December 3, 2025, following a memorandum of understanding established on August 7, 2025, which met the minimum exemption level under listing rules [1] - The memorandum has been replaced by the collaboration agreement and will automatically terminate on December 3, 2025 [1] Group 2: Product Details - The licensed product, Citric Acid Vofisilib Capsules, is a CDK4/6 inhibitor approved for treating HR+ and HER2– breast cancer [1] - This product aligns with the company's commercialization strategy in the breast cancer sector and has commercial synergies with existing breast cancer pipeline products [1] Group 3: Strategic Benefits - The introduction of the licensed product will enrich the company's pipeline and leverage its existing breast cancer commercialization team and resources to enhance future revenue scale [1]
复宏汉霖(02696)就枸橼酸伏维西利胶囊与奥鸿药业订立合作协议